TY - JOUR
T1 - Bradykinin modulates pacemaker currents through bradykinin B2 receptors in cultured interstitial cells of Cajal from the murine small intestine
AU - Choi, Seok
AU - Park, Do Young
AU - Yeum, Cheol Ho
AU - Chang, In Youb
AU - You, Ho Jin
AU - Park, Chan Guk
AU - Kim, Man Yoo
AU - Kong, In Deok
AU - So, Insuk
AU - Kim, Ki Whan
AU - Jun, Jae Yeoul
PY - 2006/8/12
Y1 - 2006/8/12
N2 - We studied the modulation of pacemaker activities by bradykinin in cultured interstitial cells of Cajal (ICC) from murine small intestine with the whole-cell patch-clamp technique. Externally applied bradykinin produced membrane depolarization in the current-clamp mode and increased tonic inward pacemaker currents in the voltage-clamp mode. Pretreatment with bradykinin B1 antagonist did not block the bradykinin-induced effects on pacemaker currents. However, pretreatment with bradykinin B2 antagonist selectively blocked the bradykinin-induced effects. Also, only externally applied selective bradykinin B2 receptor agonist produced tonic inward pacemaker currents and ICC revealed a colocalization of the bradykinin B2 receptor and c-kit immunoreactivities, but bradykinin B1 receptors did not localize in ICC. External Na +-free solution abolished the generation of pacemaker currents and inhibited the bradykinin-induced tonic inward current. However, a Cl - channel blocker (DIDS) did not block the bradykinin-induced tonic inward current. The pretreatment with Ca 2+-free solution and thapsigargin, a Ca 2+-ATPase inhibitor in endoplasmic reticulum, abolished the generation of pacemaker currents and suppressed the bradykinin-induced action. Chelerythrine and calphostin C, protein kinase C inhibitors or naproxen, an inhibitor of cyclooxygenase, did not block the bradykinin-induced effects on pacemaker currents. These results suggest that bradykinin modulates the pacemaker activities through bradykinin B2 receptor activation in ICC by external Ca 2+ influx and internal Ca 2+ release via protein kinase C- or cyclooxygenase-independent mechanism. Therefore, the ICC are targets for bradykinin and their interaction can affect intestinal motility.
AB - We studied the modulation of pacemaker activities by bradykinin in cultured interstitial cells of Cajal (ICC) from murine small intestine with the whole-cell patch-clamp technique. Externally applied bradykinin produced membrane depolarization in the current-clamp mode and increased tonic inward pacemaker currents in the voltage-clamp mode. Pretreatment with bradykinin B1 antagonist did not block the bradykinin-induced effects on pacemaker currents. However, pretreatment with bradykinin B2 antagonist selectively blocked the bradykinin-induced effects. Also, only externally applied selective bradykinin B2 receptor agonist produced tonic inward pacemaker currents and ICC revealed a colocalization of the bradykinin B2 receptor and c-kit immunoreactivities, but bradykinin B1 receptors did not localize in ICC. External Na +-free solution abolished the generation of pacemaker currents and inhibited the bradykinin-induced tonic inward current. However, a Cl - channel blocker (DIDS) did not block the bradykinin-induced tonic inward current. The pretreatment with Ca 2+-free solution and thapsigargin, a Ca 2+-ATPase inhibitor in endoplasmic reticulum, abolished the generation of pacemaker currents and suppressed the bradykinin-induced action. Chelerythrine and calphostin C, protein kinase C inhibitors or naproxen, an inhibitor of cyclooxygenase, did not block the bradykinin-induced effects on pacemaker currents. These results suggest that bradykinin modulates the pacemaker activities through bradykinin B2 receptor activation in ICC by external Ca 2+ influx and internal Ca 2+ release via protein kinase C- or cyclooxygenase-independent mechanism. Therefore, the ICC are targets for bradykinin and their interaction can affect intestinal motility.
UR - http://www.scopus.com/inward/record.url?scp=33749322296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749322296&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0706806
DO - 10.1038/sj.bjp.0706806
M3 - Article
C2 - 16783409
AN - SCOPUS:33749322296
SN - 0007-1188
VL - 148
SP - 918
EP - 926
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 7
ER -